Print page Print page
Switch language
Bispebjerg Hospital - a part of Copenhagen University Hospital

Blood Pressure Drops During Hospitalization for Acute Heart Failure Treated With Serelaxin: A Patient-Level Analysis of 4 Randomized Controlled Trials

Research output: Contribution to journalJournal articlepeer-review

  • Johannes Grand
  • Kristina Miger
  • Ahmad Sajadieh
  • Lars Køber
  • Christian Torp-Pedersen
  • Georg Ertl
  • José López-Sendón
  • Aldo Pietro Maggioni
  • John R Teerlink
  • Naoki Sato
  • Claudio Gimpelewicz
  • Marco Metra
  • Thomas Holbro
  • Olav W Nielsen
View graph of relations

BACKGROUND: Hypotensive events and drops in systolic blood pressure (SBP-drop) are frequent in patients hospitalized with acute heart failure. We investigated whether SBP-drops are associated with outcomes in patients treated with serelaxin.

METHODS: Patient-level retrospective analyses of 4 prospective trials investigating serelaxin in acute heart failure. Main inclusion criteria were SBP 125 to 180 mm Hg, pulmonary congestion, and elevated NT-proBNP (N-terminal pro-B-type natriuretic peptide). SBP-drops were prospectively defined as SBP<100 mm Hg, or, if SBP remained >100 mm Hg, a drop from baseline of 40 mm Hg from baseline. Outcomes were a short-term composite outcome (worsening heart failure, hospital readmission for heart failure or all-cause mortality through 14 days) and 180-day mortality.

RESULTS: Overall, 2559/11 226 (23%) patients had an SBP-drop. SBP-drop, versus no SBP-drop, was associated with a worse outcome: cumulative incidence of 180-day mortality (11% versus 9%, hazard ratio [HR]. 1.21 [95% CI, 1.05-1.39]; P=0.009) and the short-term outcome (11% versus 9%, HR, 1.29 [95% CI, 1.13-1.49]; P<0.001). Of the 2 SBP-drop components, an SBP<100 mm Hg was associated with the worst outcome compared with a 40 mm Hg drop: short-term outcome (11% versus 10%) and HRs of 1.32 (95% CI, 1.13-1.55; P=0.0005) and 1.22 (95% CI, 0.97-1.56; P=0.09), for each component respectively, with a P value for interaction of 0.05. SBP-drops were associated with a worse short-term outcome in the placebo group (HR, 1.46 [95% CI, 1.19-1.79]; P=0.0003), but not in the serelaxin-group (HR, 1.18 [95% CI, 0.97-1.42]; P=0.10); P interaction=0.003.

CONCLUSIONS: SBP-drops in patients with acute heart failure and normal to high SBP at admission is associated with worse short- and long-term outcomes especially for SBP <100 mm Hg. However, in patients treated with the intravenous vasodilator serelaxin, SBP-drops seemed less harmful.

REGISTRATION: URL:; Unique identifiers: NCT02064868, NCT02007720, NCT01870778, NCT00520806.

Original languageEnglish
JournalCirculation. Heart failure
Issue number4
Pages (from-to)e009199
Number of pages11
Publication statusPublished - Apr 2022

    Research areas

  • Blood Pressure/physiology, Heart Failure/diagnosis, Hospitalization, Humans, Hypotension/drug therapy, Prospective Studies, Randomized Controlled Trials as Topic, Recombinant Proteins/pharmacology, Relaxin/adverse effects, Retrospective Studies, Treatment Outcome, Vasodilator Agents/therapeutic use, hypotension, blood pressure, heart failure, hospitalization, mortality

ID: 75502624